209 related articles for article (PubMed ID: 27327137)
41. Inhibition of MicroRNA miR-222 with LNA Inhibitor Can Reduce Cell Proliferation in B Chronic Lymphoblastic Leukemia.
Dehkordi KA; Chaleshtori MH; Sharifi M; Jalili A; Fathi F; Roshani D; Nikkhoo B; Hakhamaneshi MS; Sani MRM; Ganji-Arjenaki M
Indian J Hematol Blood Transfus; 2017 Sep; 33(3):327-332. PubMed ID: 28824233
[TBL] [Abstract][Full Text] [Related]
42. Potent and sustained cellular inhibition of miR-122 by lysine-derivatized peptide nucleic acids (PNA) and phosphorothioate locked nucleic acid (LNA)/2'-O-methyl (OMe) mixmer anti-miRs in the absence of transfection agents.
Torres AG; Threlfall RN; Gait MJ
Artif DNA PNA XNA; 2011; 2(3):71-8. PubMed ID: 22567190
[TBL] [Abstract][Full Text] [Related]
43. Pharmacological inhibition of a microRNA family in nonhuman primates by a seed-targeting 8-mer antimiR.
Rottiers V; Obad S; Petri A; McGarrah R; Lindholm MW; Black JC; Sinha S; Goody RJ; Lawrence MS; deLemos AS; Hansen HF; Whittaker S; Henry S; Brookes R; Najafi-Shoushtari SH; Chung RT; Whetstine JR; Gerszten RE; Kauppinen S; Näär AM
Sci Transl Med; 2013 Nov; 5(212):212ra162. PubMed ID: 24259050
[TBL] [Abstract][Full Text] [Related]
44. In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides.
Fluiter K; ten Asbroek AL; de Wissel MB; Jakobs ME; Wissenbach M; Olsson H; Olsen O; Oerum H; Baas F
Nucleic Acids Res; 2003 Feb; 31(3):953-62. PubMed ID: 12560491
[TBL] [Abstract][Full Text] [Related]
45. Exosome-mediated delivery of functionally active miRNA-142-3p inhibitor reduces tumorigenicity of breast cancer in vitro and in vivo.
Naseri Z; Oskuee RK; Jaafari MR; Forouzandeh Moghadam M
Int J Nanomedicine; 2018; 13():7727-7747. PubMed ID: 30538455
[TBL] [Abstract][Full Text] [Related]
46. Antisense LNA-loaded nanoparticles of star-shaped glucose-core PCL-PEG copolymer for enhanced inhibition of oncomiR-214 and nucleolin-mediated therapy of cisplatin-resistant ovarian cancer cells.
Vandghanooni S; Eskandani M; Barar J; Omidi Y
Int J Pharm; 2020 Jan; 573():118729. PubMed ID: 31705975
[TBL] [Abstract][Full Text] [Related]
47. Locked nucleic acid in situ hybridization analysis of miR-21 expression during colorectal cancer development.
Yamamichi N; Shimomura R; Inada K; Sakurai K; Haraguchi T; Ozaki Y; Fujita S; Mizutani T; Furukawa C; Fujishiro M; Ichinose M; Shiogama K; Tsutsumi Y; Omata M; Iba H
Clin Cancer Res; 2009 Jun; 15(12):4009-16. PubMed ID: 19509156
[TBL] [Abstract][Full Text] [Related]
48. Demonstration of microRNA using
Warford A; Rahman NS; Ribeiro DA; Uysal Onganer P
Br J Biomed Sci; 2020 Jul; 77(3):135-141. PubMed ID: 32223721
[TBL] [Abstract][Full Text] [Related]
49. Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology.
Jepsen JS; Sørensen MD; Wengel J
Oligonucleotides; 2004; 14(2):130-46. PubMed ID: 15294076
[TBL] [Abstract][Full Text] [Related]
50. Inhibition of miR-15 protects against cardiac ischemic injury.
Hullinger TG; Montgomery RL; Seto AG; Dickinson BA; Semus HM; Lynch JM; Dalby CM; Robinson K; Stack C; Latimer PA; Hare JM; Olson EN; van Rooij E
Circ Res; 2012 Jan; 110(1):71-81. PubMed ID: 22052914
[TBL] [Abstract][Full Text] [Related]
51. Long-term inhibition of miR-21 leads to reduction of obesity in db/db mice.
Seeger T; Fischer A; Muhly-Reinholz M; Zeiher AM; Dimmeler S
Obesity (Silver Spring); 2014 Nov; 22(11):2352-60. PubMed ID: 25141837
[TBL] [Abstract][Full Text] [Related]
52. Miravirsen (SPC3649) can inhibit the biogenesis of miR-122.
Gebert LF; Rebhan MA; Crivelli SE; Denzler R; Stoffel M; Hall J
Nucleic Acids Res; 2014 Jan; 42(1):609-21. PubMed ID: 24068553
[TBL] [Abstract][Full Text] [Related]
53. Targeting miR-9 in gastric cancer cells using locked nucleic acid oligonucleotides.
Lima JF; Carvalho J; Pinto-Ribeiro I; Almeida C; Wengel J; Cerqueira L; Figueiredo C; Oliveira C; Azevedo NF
BMC Mol Biol; 2018 Jun; 19(1):6. PubMed ID: 29879907
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo.
Mook OR; Baas F; de Wissel MB; Fluiter K
Mol Cancer Ther; 2007 Mar; 6(3):833-43. PubMed ID: 17363479
[TBL] [Abstract][Full Text] [Related]
55. LNA-based oligonucleotide electrotransfer for miRNA inhibition.
Chabot S; Orio J; Castanier R; Bellard E; Nielsen SJ; Golzio M; Teissié J
Mol Ther; 2012 Aug; 20(8):1590-8. PubMed ID: 22617110
[TBL] [Abstract][Full Text] [Related]
56. Discrimination of bacteriophage infected cells using locked nucleic acid fluorescent in situ hybridization (LNA-FISH).
Vilas Boas D; Almeida C; Sillankorva S; Nicolau A; Azeredo J; Azevedo NF
Biofouling; 2016; 32(2):179-90. PubMed ID: 26813295
[TBL] [Abstract][Full Text] [Related]
57. Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92.
Morelli E; Biamonte L; Federico C; Amodio N; Di Martino MT; Gallo Cantafio ME; Manzoni M; Scionti F; Samur MK; Gullà A; Stamato MA; Pitari MR; Caracciolo D; Sesti S; Frandsen NM; Rossi M; Neri A; Fulciniti M; Munshi NC; Tagliaferri P; Tassone P
Blood; 2018 Sep; 132(10):1050-1063. PubMed ID: 29997223
[TBL] [Abstract][Full Text] [Related]
58. Locked nucleic acid and flow cytometry-fluorescence in situ hybridization for the detection of bacterial small noncoding RNAs.
Robertson KL; Vora GJ
Appl Environ Microbiol; 2012 Jan; 78(1):14-20. PubMed ID: 22057868
[TBL] [Abstract][Full Text] [Related]
59. In Situ Detection of Mature miRNAs in Plants Using LNA-Modified DNA Probes.
Yao X; Huang H; Xu L
Methods Mol Biol; 2021; 2170():143-154. PubMed ID: 32797457
[TBL] [Abstract][Full Text] [Related]
60. The adenine derivative of alpha-L-LNA (alpha-L-ribo configured locked nucleic acid): synthesis and high-affinity hybridization towards DNA, RNA, LNA and alpha-L-LNA complementary sequences.
Håkansson AE; Wengel J
Bioorg Med Chem Lett; 2001 Apr; 11(7):935-8. PubMed ID: 11294395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
